Table 3.

Investigational therapies in the pipeline for dermatomyositis.

Target	Drug	NCT	Phase	Country	Status	Primary Outcome Measures
JAK inhibitor	Baricitinib	NCT04208464	Phase 2a	UK	Not yet recruiting	Minimal, moderate, or major clinical response according to the IMACS criteria at 24 weeks
JAK inhibitor	Baricitinib	NCT04972760	Phase 3	France	Not yet recruiting	Moderate improvement based on TIS at 24 weeks without prednisone
JAK inhibitor	Tofacitinib	NCT04966884	Open Label	China	Recruiting	Number of responders by total improvement score at 12 months
Anti-interferon B monoclonal antibody	PF-06823859	NCT03181893	Phase 2	USA	Recruiting	CDASI Activity Score at 12 weeks
T-cell costimulation blockade	Abatacept	NCT02971683	Phase 3	USA	Active, not recruiting	IMACS DOI at 24 weeks
T-cell costimulation blockade	Abatacept	NCT04946669	Open label	China	Recruiting	IMACS DOI at 12 weeks
T-cell costimulation blockade	Abatacept	NCT03215927	Phase 2	USA	Recruiting	Forced Vital Capacity (FVC) % Change in 24 weeks
Complement inhibitor	Ravulizumab	NCT04999020	Phase 3	USA	Recruiting	Minimal improvement based on TIS at 26 weeks and 50 weeks